Cariprazine is a newer 3rd generation antipsychotic acting as partial agonist for dopamine receptors with unique higher affinity for D3 than D2 receptors. This review article summarizes key data from preclinical and clinical studies of cariprazine including pharmacodynamics, pharmacokinetics, clinical efficacy and safety/acceptability in acute short-term and long-term maintenance and relapse prevention therapy in patients with schizophrenia. Efficacy and safety of cariprazine in patients schizophrenia with predominantly negative symptoms resistant to previous antipsychotic therapy is discussed as well.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.17116/jnevro2021121091139 | DOI Listing |
Publication Analysis
Top Keywords
patients schizophrenia
8
[the newer
4
newer antipsychotic
4
cariprazine
4
antipsychotic cariprazine
4
cariprazine reagila
4
reagila perspectives
4
perspectives stages
4
stages schizophrenia
4
schizophrenia therapy]
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!